BRAF inhibitor

DRUG2 trials

Sponsors

Craig L Slingluff, Jr, University Hospital, Caen

Conditions

CancerMelanoma

Early Phase 1

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

TerminatedNCT02382549

Craig L Slingluff, JrMelanoma

Start: 2016-04-30End: 2022-02-28Updated: 2023-12-12

Unknown Phase

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer

University Hospital, CaenCancer

Start: 2011-01-01End: 2021-12-01Target: 16000Updated: 2021-10-15